Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced that the results of a small French trial (RespiStimALS), designed to assess the NeuRx®...
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today that it will be rolling out a new ALS trial for its NeuRx Diaphragm Pacing System ...
Synapse Biomedical (www.synapsebiomedical.com ) announced today, Dr. Raymond Onders, co-inventor of the NeuRx® Diaphragm Pacing System (DPS) and U.S. ...
Synapse Biomedical (www.synapsebiomedical.com ) has been awarded a GSA Schedule 65IIA contract and is now certified to provide goods & services to...
Results of a long-term follow up study on patients with spinal cord injuries implanted with the NeuRx® Diaphragm Pacing System (DPS) were presented...
With the support of a $3 million Ohio Third Frontier Innovation Platform Program grant, Synapse Biomedical Inc. will lead the commercialization of...
Synapse Biomedical Inc. (www.synapsebiomedical.com) reported today that the U.S. multi-center, Post Approval Study (PAS) studying the use of the...
Synapse Biomedical Inc. (www.synapsebiomedical.com) received word that the Northeast ALS Consortium (NEALS) Data and Safety Monitoring Board (DSMB)...
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today that an abstract regarding Synapse Biomedical's Post Approval Study (PAS), a...
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has completed the enrollment of the post-approval study of its NeuRx DPS®...
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has been awarded approximately $2.4 million in funding from Ohio Third...
Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has received approval from the Health Canada for its NeuRx DPS® for...
Synapse Biomedical, Inc. a annoncé que la U.S. Food and Drug Administration (FDA) avait approuvé le Système d'entrainement de diaphragme NeuRx (DPS)® ...
Synapse Biomedical, Inc. gab heute bekannt, die US-Arzneimittelbehörde (FDA) habe das NeuRx Diaphragm Pacing System(DPS)® (Zwerchfellschrittmacher)...
- Synapse Biomedical recibe la aprobación de la FDA para el NeuRx Diaphragm Pacing System (DPS)® para tratar la esclerosis lateral amiotrófica (ALS)...
Synapse Biomedical, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved its NeuRx Diaphragm Pacing System (DPS)® for...
Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.